Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus

被引：0
|
作者：
Suriya Prausmüller
Michael Resl
Henrike Arfsten
Georg Spinka
Raphael Wurm
Stephanie Neuhold
Philipp E. Bartko
Georg Goliasch
Guido Strunk
Noemi Pavo
Martin Clodi
Martin Hülsmann
机构：
[1] Medical University of Vienna,Department of Internal Medicine II
[2] Saint John of God Hospital Linz,Department of Internal Medicine
[3] Clinic Favoriten,Department of Medicine IV
[4] Complexity Research,undefined
来源：
Cardiovascular Diabetology | / 20卷
关键词：
Diabetes mellitus; Cardiovascular risk; Prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus
    Prausmueller, Suriya
    Resl, Michael
    Arfsten, Henrike
    Spinka, Georg
    Wurm, Raphael
    Neuhold, Stephanie
    Bartko, Philipp E.
    Goliasch, Georg
    Strunk, Guido
    Pavo, Noemi
    Clodi, Martin
    Huelsmann, Martin
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [2] NT-PROBNP AND HSTNT IMPROVE CARDIOVASCULAR RISK PREDICTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY OR CARDIOVASCULAR DISEASE OR BOTH
    Jhund, Pardeep
    Claggett, Brian
    Pfeffer, Marc
    Bentley-Lewis, Rhonda
    Brenner, Barry M.
    Brunel, Patrick
    Chaturvedi, Nishi
    Desai, Akshay
    Haffner, Steven
    Parving, Hans-Henrik
    Prescott, Margaret
    Solomon, Scott
    De Zeeuw, Dick
    McMurray, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1279 - A1279
  • [3] NT-proBNP to Exclude cardiovascular Complications in Patients with Type 2 Diabetes mellitus
    Resl, Michael
    Neuhold, Stephanie
    Prager, Rudolf
    Brath, Helmut
    Francesconi, Claudia
    Luger, Anton
    Pacher, Richard
    Huelsmann, Martin
    Clodi, Martin
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 : S9 - S9
  • [4] NT-proBNP to Exclude cardiovascular Complications in Patients with Diabetes mellitus Type 2
    Resl, M.
    Huelsmann, M.
    Pacher, R.
    Luger, A.
    Clodi, M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2013, 125 (17-18) : 559 - 559
  • [5] NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus
    Malachias, Marcus V. B.
    Jhund, Pardeep S.
    Claggett, Brian L.
    Wijkman, Magnus O.
    Bentley-Lewis, Rhonda
    Chaturvedi, Nishi
    Desai, Akshay S.
    Haffner, Steven M.
    Parving, Hans-Henrik
    Prescott, Margaret F.
    Solomon, Scott D.
    De Zeeuw, Dick
    McMurray, John J., V
    Pfeffer, Marc A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (19):
  • [6] The Use of NT-proBNP for Risk Stratification of Incident Cardiorenal Complications in Type 2 Diabetes-The Hong Kong Diabetes Biobank
    Ma, Ronald C. W.
    Tam, Claudia H.
    Hou, Yong
    Jin, Qiao
    Lau, Eric S. H.
    Ozaki, Risa
    Kong, Alice P.
    Chow, Elaine
    Luk, Andrea
    Lim, Cadmon K. P.
    Chan, Juliana C.
    DIABETES, 2023, 72
  • [7] Rationale for the testingof cardiovascular risk in patients with COX-2 inhibitors with the biomarker NT-proBNP
    Giannitsis, E
    CLINICAL LABORATORY, 2005, 51 (1-2) : 73 - 83
  • [8] Galectin-3 for prediction of cardiac function and comparison to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus
    Schmitt, Volker H.
    Prochaska, Juergen H.
    Foell, Annegret S.
    Schulz, Andreas
    Keller, Karsten
    Hahad, Omar
    Koeck, Thomas
    Troebs, Sven-Oliver
    Leuschner, Anja
    Arnold, Natalie
    Rapp, Steffen
    Zeller, Tanja
    Beutel, Manfred
    Pfeiffer, Norbert
    Strauch, Konstantin
    Lackner, Karl J.
    Muenzel, Thomas
    Wild, Philipp S.
    INTERNIST, 2021, 62 (SUPPL 2): : 173 - 173
  • [9] High-Sensitivity Cardiac Troponin T and NT-proBNP in Cardiovascular Risk Prediction in Persons with Diabetes
    Parrinello, Christina M.
    Mcevoy, John W.
    Woodward, Mark
    Folsom, Aaron R.
    Ballantyne, Christie M.
    Coresh, Josef
    Selvin, Elizabeth
    DIABETES, 2014, 63 : A351 - A351
  • [10] Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP
    Giannitsis, E
    CLINICAL LABORATORY, 2005, 51 (1-2) : 63 - 72
12345